The Lunar Polar Hydrogen Mapper (LunaH-Map) Mission

The Lunar Polar Hydrogen Mapper (LunaH-Map) mission will map hydrogen enrichments within permanently shadowed regions at the lunar south pole using a miniature neutron spectrometer. While hydrogen enrichments have been identified regionally from previous orbital missions, the spatial extent of these regions are often below the resolution of the neutron instruments that have flown on lunar missions. LunaH-Map will enter into an elliptical, low altitude perseline orbit which will enable the mission to spatially isolate and constrain the hydrogen enrichments within permanently shadowed regions. LunaH-Map will use a solid iodine ion propulsion system, X-Band radio communications through the NASA Deep Space Network, star tracker, C&DH and EPS systems from Blue Canyon Technologies, solar arrays from MMA Designs, LLC, mission design and navigation by KinetX. Spacecraft systems design, integration, qualification, test and mission operations are performed by Arizona State University

The Molecular Taxonomy of Primary Prostate Cancer

There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course. As part of The Cancer Genome Atlas (TCGA), we present a comprehensive molecular analysis of 333 primary prostate carcinomas. Our results revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1). Epigenetic profiles showed substantial heterogeneity, including an IDH1 mutant subset with a methylator phenotype. Androgen receptor (AR) activity varied widely and in a subtype-specific manner, with SPOP and FOXA1 mutant tumors having the highest levels of AR-induced transcripts. 25% of the prostate cancers had a presumed actionable lesion in the PI3K or MAPK signaling pathways, and DNA repair genes were inactivated in 19%. Our analysis reveals molecular heterogeneity among primary prostate cancers, as well as potentially actionable molecular defectsclose